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A B S T R A C T
Background: Worldwide, millions of women seek treatment for early pregnancy loss (EPL) annually. Medical
management with misoprostol is widely used, but only effective 60% of the time. Pre-treatment with mifep-
ristone prior to misoprostol might improve the success rate of medical management.
Methods: This was a multi-centre, double-blind, placebo-controlled randomised trial in 17 Dutch hospitals.
Women with a non-viable pregnancy between 6 and 14 weeks of gestation were eligible for inclusion after
at least one week of expectant management. Participants were randomised (1:1) between oral mifepristone
600 mg or an oral placebo tablet. Participants took 400 mg misoprostol orally, repeated after four hours on
day two and, if necessary, day three. Primary outcome was expulsion of gestational sac and endometrial
thickness <15 mm after 68 weeks. Analyses were done according to intention-to-treat principles. This trial
is registered with ClinicalTrials.gov, NCT03212352.
Findings: Between June 28th 2018 and January 8th 2020, 175 women were randomised to mifepristone and
176 to placebo, including 344 in the intention-to-treat analysis. In the mifepristone group 136 (791%) of
172 participants reached complete evacuation compared to 101 (587%) of 172 participants in the placebo
group (p<00001, RR 135, 95% CI 116156). Incidence of serious adverse events was significantly lower
in the mifepristone group with 24 (14%) patients affected versus 55 (32%) in the placebo group (p = 00005)
(Table 3).
Interpretation: Pre-treatment with mifepristone prior to misoprostol was more effective than misoprostol
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1. Introduction
Early pregnancy loss (EPL) is defined as a non-viable first trimes-
ter intra-uterine pregnancy, in which there may be an anembryonic
gestation or embryonic death [1,2]. It is a common outcome of preg-
nancy, occurring in 1028% of pregnancies with rates varying by age
[3,4]. The estimated annual number of pregnancies worldwide is
227 million, meaning every year millions of women will seek treat-
ment for EPL [5]. It is essential that EPL treatment is optimised, allow-
ing women to receive the most effective and safe treatment while
meeting their personal needs and rights.
Three treatment options exist for EPL: expectant, surgical, or med-
ical. In many European countries, including the Netherlands, expec-
tant management for at least one week is common practice, as it is
well known that a spontaneous complete evacuation can occur in up
to 50% of women [6,7]. However, after this period of expectant man-
agement, the remainder of women, in which no spontaneous evacua-
tion occurred may require treatment. Although very successful in
reaching complete evacuation, surgical management, i.e., uterine
aspiration, is associated with risks of early and late complications,
such as adhesion formation and increased risk of premature delivery
in subsequent pregnancies, and higher costs [810]. Multiple inter-
national guidelines such as, for example from the American College
of Obstetrics and gynecology (ACOG) and the guideline from the
National Institute for Health and Care Excellence (NICE), currently
recommend misoprostol as primary medical treatment of EPL, with
some suggesting mifepristone pre-treatment and others advising
against the use of mifepristone [2,11]. Misoprostol tablets, a prosta-
glandin E1 analogue, are widely used, easy to apply, proven safe, and
do not require special storage or temperature conditions [2,11,12].
Medical management using misoprostol without previous expectant
management may result in success rates of 660885% [13,14].
After one week of expectant management, the success rate of miso-
prostol treatment decreases to 54% [15,16]. Thus, surgical treatment
is associated with risks and higher costs, but medical treatment with
misoprostol is limited in terms of its efficacy.
The sequential combination of mifepristone followed by miso-
prostol has been shown to be superior to misoprostol alone for the
termination of viable first trimester pregnancies, and for labour
induction following foetal death in utero in the second or third tri-
mester [17,18]. Mifepristone acts by binding tightly to the progester-
one receptor, thus blocking the action of progesterone. This results in
the breakdown of the decidua, increasing prostaglandin levels and
inducing a higher sensitivity of the uterus towards prostaglandins,
leading to uterus contractions and the possible expulsion of the blas-
tocyst [19]. It is therefore hypothesised that this combination will
also be a more successful treatment of EPL than misoprostol alone.
Both a retrospective study and a pilot study (unpublished data)
performed by our research group [16], and two recently published
trials show an advantage of pre-treatment with mifepristone for the
treatment of EPL [20,21]. However, the evidence supporting pre-
treatment with mifepristone remains insufficient, leading to conflict-
ing recommendations in the NICE and ACOG guidelines [2,11]. A
recent systematic review and meta-analysis concluded that the cur-
rent evidence for the addition of mifepristone is ‘limited’ [22], and
the most recent Cochrane review classified the evidence level as
‘very low’ [23]. Taken together, evidence from a large, sufficiently
powered, placebo-controlled, double-blinded randomised controlled
trial (RCT) is needed.
The aim of the Triple M Trial (Mifepristone and Misoprostol for Mis-
carriage) was to compare the sequential combination of mifepristone
with misoprostol with the use of a placebo followed by misoprostol
in the treatment of EPL, in terms of complete evacuation, side effects
and complications, in a placebo-controlled double-blind RCT.
2. Methods
2.1. Study design
This randomised, placebo-controlled, double-blinded trial was
performed in a total of 17 centres in the Netherlands, 1 district, 14
teaching and 2 tertiary referral hospitals. The participants were fol-
lowed in an outpatient setting, unless admission was medically nec-
essary. Ethical approval to conduct the study was obtained from the
regional medical-ethical commission (Commissie Mensgebonden
Onderzoek Arnhem-Nijmegen). The study protocol is available from
https://doi.org/10.1186/s128840192497-y.24
This trial was registered at the following registers:
Clinicaltrials.gov: NCT03212352.
Trialregister.nl: Trial NL 6366
EudraCT number: 2017-002694-19.
File number Commissie Mensgebonden Onderzoek: NL
62449.091.17.
2.2. Participants
Women 16 years of age or older, with an ultrasound examination
showing a non-viable intra-uterine pregnancy between 6 and 14
weeks of gestation, who had been managed expectantly for at least
one week, were eligible for inclusion. The diagnosis of EPL was made
Research in context
Evidence before this study
Early pregnancy loss (EPL) occurs in 10 to 28% of all pregnan-
cies. Medical treatment for EPL is found to be a safe and effec-
tive alternative for surgical treatment. Although a number of
studies have been performed, there is limited evidence regard-
ing the addition of mifepristone to treatment with misoprostol
alone in case of EPL. This is reflected by different recommenda-
tions in international guidelines.
Added value of this study
This large, sufficiently powered, double-blinded placebo-con-
trolled randomized trial demonstrates that the sequential com-
bination of mifepristone with misoprostol is more effective
than misoprostol alone in case of EPL.
Implications of all the available evidence
Our findings support the implementation of pre-treatment with
mifepristone in case of EPL in (inter)national guidelines. The
sequential combination of mifepristone and misoprostol is easy
to use and more effective in reaching complete miscarriages,
thereby preventing the need for uterine aspiration and its pos-
sible complications.
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by ultrasonography describing: A crown-rump length (CRL)  6 mm
and no cardiac activity, or a CRL <6 mm and no embryonic growth at
least one week later, or a gestational sac with absent embryonic pole
for at least 1 week.
In case of an obvious discrepancy of at least one week between
the crown and rump length of the non-viable embryo and the calen-
dar gestational age, women were also eligible for inclusion, as a week
of expectant management had already been applied unknowingly.
Women who were haemodynamically unstable, or who showed
signs of infection or incomplete miscarriage were excluded, as well
as patients with contraindications to mifepristone or misoprostol.
Women were also excluded if they had a known clotting disorder or
used anticoagulants, had (risk factors for) cardiovascular disease, or if
there was a language barrier hindering adequate counselling.
Eligible women were identified and approached to participate in
the study by their treating physician. They were then counselled by
trained staff informing them about the aims, methods, reasonable
anticipated benefits, and potential hazards of the study medication,
and were given the patient information letter. Patients were also
informed about the off-label use of both mifepristone and misopros-
tol. Participation was voluntary, and patients could withdraw their
consent to participate at any time during the study. The investigator
could also decide to withdraw a participant from the study for urgent
medical reasons. Baseline demographics, obstetric and medical his-
tory were recorded for all women at the time of randomisation using
a case report form. Immediately after obtaining oral and written
informed consent, randomisation was performed.
2.3. Randomisation and masking
Subjects were randomised in a 1:1 ratio to either mifepristone
600 mg orally or placebo pre-treatment using computerised random-
isation tables. Randomisation was conducted by block randomisation,
with a block size of eight, stratified by hospital. The randomisation
tables were generated by two independent physicians, who had no
further role in the execution of the trial.
After informed consent was obtained, the treating physician took
the first available study number from the computerised randomisa-
tion table. Thus, a unique study number was assigned to each partici-
pant. This unique study number corresponded with identical looking
medication jars available in the participating centres, containing the
study medication.
For the purpose of this study, the Clinical Trials Unit in the Rad-
boud university medical centre (Radboudumc) ordered batches of
mifepristone and placebo tablets. The placebo tablets consisted
mainly of maize starch and lactose, and were visually identical to
mifepristone tablets, without containing active medication.
Three tablets were repackaged into identical medication jars,
labelled with the unique study number, following the randomisation
table. The content of each medication jar was unknown to all
involved in the study, establishing double blinding. After repackaging
and labelling, the blinded medication jars were distributed to all par-
ticipating hospitals. A sealed list with the contents of each medication
jar was available for deblinding in the Clinical Trials Unit of the Rad-
boudumc in case of emergency. The data from this list was disclosed
to the investigators not earlier than 16th April 2020, after the results
of all outcome parameters had been collected for all participants.
Regarding misoprostol, the treating physician prescribed these
tablets as usual, which were provided by the patients’ own/local
pharmacies.
2.4. Procedures
The mifepristone tablets and visually identical placebo tablets
were purchased at a regular price from Excelgyn (Groupe Nordic
Pharma) for the purpose of this study. All medication was produced
in Paris, France. Excelgyn had no further role in the design, conduct,
or analysis of this trial.
After informed consent was obtained, and randomisation per-
formed, each patient received three tablets containing either 200 mg
mifepristone or the placebo. These three tablets were taken by the
participant on day one.
With the exception of the blinded study medication intake, the
further management of all participants was equal in both groups. At
day three (3648 h later), two doses of misoprostol 400 mg orally
(four hours apart) were taken at home. Participants were instructed
to observe their blood loss and loss of possible products of concep-
tion. If blood loss had not occurred, or if blood loss had occurred and
the participant’s subjective assessment was that no tissue had passed
by day four, participants were instructed to take two more doses of
misoprostol 400 mg orally (four hours apart).
To assess the treatment effect, a first follow-up visit including
ultrasonography was performed between day 15 and 20, so after
approximately two weeks. In case of an expulsed gestational sac and
a total endometrial thickness (TED) < 15 mm determined using ultra-
sonography, no further evaluation was necessary, and the treatment
was considered successful.
In the case of an expulsed sac but possible retained products of
conception (RPOC) defined as TED > 15 mm, expectant management
was advised, with consent from the patient, for another four weeks.
If the gestational sac was still retained in utero after this period, or
there was another reason for intervention, the treatment was consid-
ered unsuccessful and additional treatment was offered.
The primary outcome was assessed at six to eight weeks after the
treatment start, when ultrasonography was performed to evaluate
endometrial thickness. In case of an endometrial thickness > 15 mm,
further treatment was performed according to local protocol and
patient preference. Additional treatment was either expectant, medi-
cal (another course of misoprostol), or surgical (hysteroscopy or uter-
ine aspiration).
During all follow-up visits, including unplanned and emergency
visits, clinical signs and symptoms were assessed in addition to the
ultrasonographic findings. When deemed necessary by the treating
physician, additional treatment was offered and documented.
If successful uterine aspiration was performed after the primary
medical treatment, no further examinations were scheduled for the
purpose of this study. If the initial allocated treatment failed, patients
were followed until complete evacuation of the uterus was estab-
lished.
Anti-D prophylaxis was given as part of standard treatment to
patients with an gestational age of at least 10 weeks, or if instrumen-
tation took place, following the relevant Dutch guideline [25].
All participants were asked to fill out a patient diary, indicating
how and when they took the medication. Additionally, they were
asked to use the diary to report any adverse reaction after the admin-
istration of the study medication and/or misoprostol, up until the first
follow-up visit. Participants were also asked to complete question-
naires regarding their quality of life and productivity loss at four dif-
ferent timepoints (T = 0, 1, 2 and 6 weeks after treatment start). The
participants were able to contact their hospital 24 h a day in case of
questions, complaints, or emergencies during the course of the study.
2.5. Outcomes
The primary study outcome was the successful treatment or com-
plete evacuation of the uterus (defined as an expelled gestational sac
and an endometrial thickness < 15 mm determined using ultraso-
nography) using only the allocated therapy by randomisation, and
was determined 68 weeks after the initial treatment [26].
The secondary outcomes included any additional interventions
required to achieve complete evacuation, such as uterine aspiration,
additional medical treatment, or hysteroscopy, as well as any adverse
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reactions. Safety outcomes consisted of (serious) adverse events
(SAEs) and adverse reactions. An SAE is defined as an ‘undesirable
medical event in a patient or test subject, not necessarily related to
the treatment and results in: death, and/or is life-threatening, and/or
requires inpatient hospitalization or causes prolongation of existing
hospitalization, and/or results in persistent or significant disability/
incapacity, and/or may have caused a congenital anomaly/birth
defect, and/or requires intervention to prevent permanent
impairment or damage [27,28]. An adverse reaction is defined as any
adverse event for which there is a reasonable possibility that the
drug caused the adverse event, but does not meet the criteria for an
SAE, and in layman’s terms is often referred to as a side-effect
[27,28].
Participating centres were asked to promptly report any (sus-
pected) SAE to the coordinating investigator and fill out a SAE form.
Using this form, the coordinating investigator reported all SAEs to
the Medical Ethical Committee within 15 days. An exception was
made for the reporting of uterine aspirations, as this is a common
procedure in the treatment process of EPL [29]. All cases of uterine
aspiration were registered as SAEs and reported to the Medical Ethi-
cal Committee in the obligatory semi-annual safety reports.
Additional pre-specified outcomes such as the acceptability of
treatment, quality of life, cost-effectiveness, and assessment of
patient and clinical characteristics associated with complete evacua-
tion were collected. These data are not presented here but are to be
published in the near future.
2.6. Statistical analysis
The sample size calculation was based on data from a previous
retrospective study, with a complete evacuation rate of 67% in the
intervention group (mifepristone 600 mg orally 3648 h before
misoprostol) and 54% in the control group (misoprostol only) [16].
These findings are comparable with other data from the literature
[15,30,31]. Based on these evacuation rates and an overall signifi-
cance level of 5% (a = 005), in combination with a power of 80%
(b = 020), the trial required 221 patients in each arm. Anticipating
4% lost to follow-up, based on the percentage of lost to follow-up in
our pilot-study (2.5%), 230 patients had to be included per arm.
Because of the intended execution of an interim analysis after inclu-
sion and the outcome assessment of 50% of intended inclusions, the
sample size was adjusted to 232 patients per arm (total 464), to
maintain a sufficiently powered final analysis.
In case of missing data the specific hospital was contacted to
retrieve the missing information as much as reasonably possible.
A Data Safety Monitoring Board oversaw the study and assessed
the results of the interim analysis after 50% of inclusions regarding
primarily effectivity and secondarily safety. A pre-defined stopping
rule, according to O’Brien-Fleming, was used to assess the primary
outcome, complete evacuation after 68 weeks [24]. Following this
stopping rule, when analysis of the primary outcome would show a
difference between both study groups with a p-value <0.0054, a pre-
mature halt of the trial would be justified.
Frequencies and proportions were calculated for categorical val-
ues. Means or medians were calculated for continuous variables,
depending on normality.
The proportion of success in each arm was compared using a two-
sample test for proportions (Chi-square or Fisher’s exact test). The
relative risks were calculated with a 95% confidence interval.
An intention-to-treat analysis was performed for both the primary
outcome, and the secondary and safety outcomes. All analyses were
performed using SPSS version 26 (IBM Corp. Released 2019. IBM SPSS
Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.)
2.7. Role of the funding source
The funders of the study had no role in the study design, data col-
lection, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data of the study
and had the final responsibility for the decision to submit for publica-
tion.
3. Results
Between 27th June 2018, and 8th January 2020, a total of 351
patients were enrolled and randomised into the treatment groups.
Although the planned interim analysis was set at 50% (232 patients),
an additional 119 patients were included before the trial was stopped
due to the time lapse between the inclusion of the 232nd patient and
the advice given by the Data Safety Monitoring Board to halt the trial.
This time lag was caused by the follow-up period, acquiring the data,
and performing the interim analysis. The Data Safety Monitoring
Board advised the halting of the trial on 27th December 2019, based
on the superiority of one of the treatments. There were no concerns
reported with regards to patient safety. Data regarding all 351
included patients will be reported here.
As shown in Fig. 1, a total of 175 patients were assigned to the
treatment with mifepristone and 176 to the placebo, both followed
by the standard misoprostol treatment. In each study arm, two
patients withdrew consent a few hours after randomisation, before
taking the blinded study medication; these patients were excluded
from the analysis. In the mifepristone arm, one patient was excluded
after randomisation, as she was found to have a cornual pregnancy
not meeting the inclusion criteria. In the placebo arm, two patients
were lost to the follow-up, as they did not attend their planned fol-
low-up visits, nor responded to attempted contact by their doctor,
and were excluded from the analysis. In both arms, 172 participants
were included in the intention-to-treat analysis.
The baseline characteristics of the study population were similar
between both groups (Table 1). In 69% of patients, an embryo without
cardiac activity was seen. EPL in at least one previous pregnancy had
occurred in 30% of patients in both groups. In both groups, 20
patients (116%) had a gestational age above 12 weeks, with a mean
crown-rump length of 2224 mm (§2598).
The primary outcome is presented in Table 2: at 68 weeks after
the start of the treatment, using only the allocated therapy, 136/172
patients (791%) in the mifepristone group had reached complete
evacuation versus 101/172 (587%) in the placebo arm (p<00001,
RR 135, 95% CI 116156). A sensitivity analysis that assumed the
outcomes in the two women who were lost to follow-up were in
favour of no treatment effect (p<00001, RR 195, 95% CI
138274) did not alter the results. After the first follow-up visit at
two weeks, 107/172 patients in the mifepristone group (622%) had
already reached a complete evacuation versus 78/172 (453%) in the
placebo group (p = 0001, RR 137, 95% CI 112168). A total of 59
patients (25 in the placebo group and 34 in the mifepristone group)
were asked to return four weeks later because of suspected retained
products of conception (RPOC), without applying a further interven-
tion such as another course of medication or antibiotic prophylaxis.
Spotting per vaginam was present in 36 (610%) of these patients. At
the second follow-up an additional 41/59 (695%) patients had
reached complete evacuation.
Table 2 also lists the additional treatment given if the allocated
therapy did not lead to a complete evacuation. The number of
patients requiring at least one additional treatment was 36 in the
mifepristone arm and in 71 the placebo arm. Uterine aspiration was
performed less often in the mifepristone group (19/172 patients or
110%) than in the placebo group (51/172 patients or 297%)
(p<00001, RR 037, 95% CI 023060). Emergency uterine
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aspiration due to heavy vaginal bleeding was performed in three
patients in the mifepristone group and eight patients in the placebo
group.
Of the patients who did not reach a complete evacuation at the
first follow-up visit at two weeks, 14 (81%) patients in the mifepris-
tone group opted for another course of misoprostol, which was sig-
nificantly fewer than the number in the placebo group (27, 157%)
(p = 00305). This additional course of misoprostol led to complete
evacuation in 6/14 (429%) in the mifepristone and 13/27 (481%) in
the placebo group. The remaining patients required another addi-
tional treatment. The rate of hysteroscopies for the treatment of
RPOC was similar between the mifepristone and the placebo group
(6.4% and 5.2% respectively). All hysteroscopies were performed
based on suspected intra-uterine remains visible on an ultrasound at
the second follow-up appointment at 68 weeks after treatment
start.
A total of 79 SAEs were recorded, as shown in Table 3. The
SAEs consisted mainly of short stay hospital admissions of less
than a day, for uterine aspiration, comprising 19/24 (792%) of
the mifepristone group and 51/55 (927%) of the placebo group.
Other reasons for admission were clinical hysteroscopy or the
observation of excessive blood loss. Significantly fewer SAEs were
observed in the mifepristone group (24 SAEs) than in the placebo
group (55; p = 00005). The rate of SAEs other than hospital
admission was 0.6% and 1.2% in the mifepristone and placebo
group respectively. A pelvic infection was suspected in one
patient in each study group (06%), and both were treated with
oral antibiotics (Augmentin). One patient in the placebo group
required a blood transfusion following heavy bleeding.
Table 4 shows the incidence of the six most frequent adverse reac-
tions, as reported in the patient diaries kept for the first two weeks.
This diary was completed and returned to their treating physician by
78% of patients, 133 in the mifepristone group and 137 in the placebo
group. The diaries showed a medication compliance rate of 90.7%
overall, comparable between both groups. In the mifepristone group,
80/133 (602%) patients reported at least one adverse reaction, which
was significantly more than the 65/137 (477%) patients reporting an
adverse reaction in the placebo group (p = 0024, RR=127, 95% CI
101159). The mean number of adverse reactions per patient did
not differ significantly between both groups. The percentage of
patients experiencing an adverse reaction from the study medication
only was 15.9% overall, and not significantly different between
groups (p = 0.0652). Nausea and dizziness were reported significantly
more frequently in the mifepristone group (p = 0007 and p = 0034,
respectively) during the misoprostol intake on days three and four.
All other adverse reactions occurred in fewer than 5% of patients, and
were similarly distributed between both treatment groups.
4. Discussion
The results of this trial show that, after the expectant manage-
ment of EPL for one week, the sequential combination of mifepristone
and misoprostol is superior to a treatment of a placebo and misopros-
tol for reaching a complete evacuation of the uterus within six weeks,
Fig. 1. trial profile
Legend:———> = included in intention-to-treat analysis
! = excluded from intention-to-treat analysis.
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with a number needed to treat (NNT) of 49. Additionally, this com-
bined treatment leads to significantly fewer patients requiring addi-
tional surgical treatment. The Triple M Trial was halted prematurely
because the highly significant results of the pre-planned interim
analysis met the pre-defined stopping rule (see study protocol).
There were no concerns regarding safety of the participants, as SAEs
occurred more often in the placebo group receiving current standard
treatment, and adverse reactions (although occurring more often in
the mifepristone group) were mild. Our findings extend those from
previous trials, thus adding to the existing body of evidence in favour
of mifepristone pre-treatment [21,32].
Pre-treatment with mifepristone was previously shown to
improve uterine evacuation in cases of first trimester medical abor-
tion and after second or third trimester foetal death [17,18]. The
results of the present study are also in accordance with previous
studies by both our own and other research groups on the efficacy of
mifepristone in the treatment of EPL [16,20,21]. Our retrospective
study and pilot study (unpublished data) both revealed an advantage
of the addition of mifepristone to the treatment with misoprostol
[16], with NNTs of 84 and 35, respectively. Schreiber et al. recently
performed a RCT, without one week of expectant management prior
to inclusion, of a comparable size (N = 300), finding an advantage of
pre-treatment with mifepristone, with a NNT of 6; [21] however, no
placebo was given to the control group, thus introducing potential
bias as stated by the Cochrane group in their most recent systematic
review regarding medical treatment of early foetal death [23]. In their
study, successful treatment was defined as the loss of the gestational
sac by day four, with no additional treatment within 30 days. Sinha
et al. performed a smaller (N = 92) RCT, again without one week of
expectant management, showing an advantage of pre-treatment
with mifepristone, with a NNT of 35 [20]. Successful treatment was
defined as the loss of the gestational sac and a TED < 15 mm on
day 14.
Until now, irrefutable evidence regarding the role of mifepristone
pre-treatment has been lacking, which may have led to the different
recommendations in various guidelines. The ACOG recently revised
its guideline regarding EPL, and now recommends that clinicians con-
sider the use of mifepristone prior to treatment with misoprostol
[11]. The ACOG does not recommend an expectant policy for the first
week [11], which is more common in European guidelines. The NICE
guideline recommends an expectant policy for at least one week; [2]
however, this recently updated guideline still advices against the use
of mifepristone.
This study is unique in terms of optimal design, which is a key
strength enabling us to draw firm conclusions about the effect of
mifepristone on the outcomes. The risk of bias was minimised by ran-
domisation using a computerised number table, sequentially num-
bered drug containers of identical appearance, and the use of visually
identical placebo tablets as study medication for the blinding of par-
ticipants and medical personnel.
A limitation of this trial might be the fact that our choices con-
cerning inclusion criteria, route and dosages of medication, and the
timing of follow-up are not applicable in all settings, as healthcare
may be arranged differently, and circumstances may vary, in different
countries. We will now elucidate the choices we made in designing
our trial. The fact that women were only eligible for participation
after at least one week of expectant management may be seen by
some as a limitation of this study, as it is not recommended in all cur-
rent guidelines. However, this can also be considered a strength, as it
shows the effect of mifepristone in a group of women who are
Table 2
Clinical outcomes.
Mifepristone and misoprostol (N = 172) Placebo and misoprostol (N = 172) p-value
Primary outcome
Complete evacuation achieved with only allocated therapy 136 (79.1%) 101 (58.7%) <0.0001
Patients requiring additional intervention* 36 71
Uterine aspiration 19 (11.0%) 51 (29.7%) <0.0001
Indication
- Patients request 7 20
- complete GS remaining in utero 5 12
- suspected intra-uterine remains on ultrasound 4 9
- heavy blood loss 3 7
- suspected intra-uterine infection 0 3
Emergency setting 3 (1.7%) 8 (4.7%)
Extra course misoprostol after first follow-up 14 (8.1%) 27 (15.7%) 0.022
successful 6 13
Hysteroscopy (operative) 11 (6.4%) 9 (5.2%) 0.409
* Some patients required more than one additional treatment to achieve complete evacuation. Therefore, the total number of additional treatments is








Mean (SD) 32.95 (4.39) 32.69 (4.30)
BMI (kg/m2)
Mean (SD) 24.70 (4.44) 24.08 (3.84)
Unknown 28 34
Race or ethnic group
Caucasian 156 (90.7%) 155 (90.1%)
Other 12 (7.0%) 13 (7.6%)
Unknown 4 (2.3%) 4 (2.3%)
Gravidity
1 60 (34.9%) 75 (43.6%)
2 63 (36.6%) 53 (30.8%)
 3 49 (28.5%) 44 (25.6%)
Parity
0 83 (48.3%) 94 (54.7%)
1 70 (40.7%) 64 (37.2%)
19 (11.0%) 14 (8.1%)
Gestational age based on
amenorrhoea (days)





123 (71.5%) 115 (66.9%)
Anembryonic gestation 49 (28.5%) 57 (33.1%)




13 (25.5%) 19 (36.5%)
Of these: successful
misoprostol treatment
7 (53.8%) 12 (63.2%)
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unlikely to spontaneously miscarry. As women who miscarry sponta-
neously are excluded by this week of expectant management, unnec-
essary treatment is prevented.
The dosage of mifepristone 600 mg is higher than the WHO-rec-
ommended 200 mg for medical abortions [33]. We followed the man-
ufacturers recommendation regarding the dosage of mifepristone.
Additionally, one could argue that non-viable pregnancies may
require higher dosages of mifepristone after one week of expectant
management, as they remain intra-uterine regardless of foetal
demise. This might especially be the case for our population, with
whom a week of expectative management had already been applied.
Furthermore, a dosage of 600 mg mifepristone may not necessarily
lead to more side effects compared to 200 mg. In fact, and surpris-
ingly, the higher dosage of 600 mg has even been reported to cause
significantly fewer side effects and less pain during the expulsion of
the products of conception [34]. Both Sinha et al. and Schreiber et al.
used 200 mg mifepristone, and report far higher frequencies of the
most common patient-reported adverse reactions (up to 792% and
422%, respectively) [20,21], compared with the 256% frequency
reported in this study. Future research in this particular population
may provide clarity about the preferable dosage in relation to efficacy
and adverse reactions.
Regarding misoprostol, many different treatment regimens are
being used, as the superior regimen regarding dosage and route of
administration for misoprostol remains unclear to date [23]. We
chose the oral admission of 800 mg misoprostol, divided over two
doses per day. A split dosage of misoprostol (two or three doses of
400 mg) has been reported to be similarly successful to a protocol
using 800 mg at once [35]. As gastrointestinal side effects are dose-
and interval-dependent, we chose a split dosage with the aim of
reducing side effects as far as possible [36]. This also gives patients
the option to omit the second dose of 400 mg if a strong reaction has
occurred to the first dose. In addition, the oral route is more practical
and might be preferred by patients, compared to the vaginal route,
although evidence is conflicting [37,38]. The additional second-day
administration of misoprostol is common practice in the Netherlands.
This procedure is based on the self-assessment of loss of tissue by the
prior-instructed patient. The administration of misoprostol on day
four was thus not seen as a failure.
The primary outcome was determined as an ultrasonographically
confirmed expulsion of the gestational sac, with an endometrial
thickness of < 15 mm. Previous studies do not provide any clear evi-
dence about which ultrasonographic endometrial thickness best cor-
responds to the presence of retained products of conception (RPOCs)
[39,40]. Based on the results of their study, Lavecchia et al. concluded
that a maximum anteriorposterior diameter of 15 mm or less meant
that RPOCs were less likely to be confirmed histologically [26]. Sev-
eral studies published in the last decade report the use of an endome-
trial thickness of <15 mm to assess the presence of RPOC [4143].
This was also found in a recent systematic scoping review, investigat-
ing the assessment of complete uterine evacuation or the presence of
RPOC [44]. The primary outcome was assessed at 68 weeks after
the start of the treatment, which is a substantially longer follow-up
period than the aforementioned studies. All participants were fol-
lowed until compete evacuation was achieved. This longer follow-up
period was chosen as it allows for a more reserved policy, preventing
possible unnecessary additional interventions, as recently shown by
the MisoREST study [45]. In this trial, Lemmers et al. studied the
treatment of women with an endometrium of 10 mm or more on
ultrasound one to two weeks after the treatment of EPL with miso-
prostol. These women were then randomised to undergo either
expectant or surgical management. Their results show that an expec-
tant policy is fully justifiable for at least six weeks, and was found to
be just as safe as prompt uterine aspiration planned after two weeks,
thus preventing surgery in 85% of these women. Additionally, this
policy was preferred by most women, showing a significantly lower
quality of life in the group receiving prompt uterine aspiration com-
pared to women receiving expectant management [46]. It has been
proven that patients who get to choose their preferred treatment
have a better health-related quality of life [47]. As early pregnancy
loss is an intense and distressing life event, it is of utmost importance
to take patient preferences into account.
In addition to these considerations, it is important to realize that,
in contrast to other countries, in the Netherlands a surgical uterine
evacuation involves, although usually short stay, hospitalization of
the patient. This will have led to a higher amount of SAE’s in our trial
compared to other trials, especially in the placebo group. If this fact is
not taken into account it might lead to a distorted picture of the
amount and ratio of SAE’s in both study groups. The low rate of SAE’s
other than hospitalization for surgical uterine evacuation is compara-
ble to that of other studies [20,21,32].
In spite of differences regarding treatment regimens, setting and
arrangement of healthcare, our robust design ensures our results are















23 (13.4%) 53 (30.8%) 0.000579
Planned 17 (9.9%) 44 (25.6%)




Unplanned 6 (3.5%) 9 (5.2%)


































1.28 (1.39) 1.03 (1.34) 0.136
Side effect - no of
patients reporting
this
Diarrhoea 29 (21.8%) 34 (24.8%) 0.330
Nausea 34 (25.6%) 18 (13.1%) 0.007
Severe cramping 20 (15.0%) 15 (10.9%) 0.207
Upset stomach 10 (7.5%) 12 (8.8%) 0.441
Headache 10 (7.5%) 8 (5.8%) 0.379
Dizziness 16 (12.0%) 7 (5.1%) 0.034
*Patients were asked to report any adverse reaction they noticed. The total num-
ber of reported adverse reactions is therefore higher than the number of patients
reporting adverse reactions.
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of patients suffering an EPL, in different settings regarding the kind of
hospital patients are referred to, and applied current practice as the
control group.
The growing evidence supporting mifepristone pre-treatment in
EPL has important implications worldwide. Mifepristone was first
introduced in France in 1987, and since the patent expired prices
have already dropped drastically. Both mifepristone and misoprostol
do not require special storage conditions and can be kept at room
temperature, enabling a more widespread use in low-income coun-
tries.
More effective medical treatment of EPL after a period of expec-
tant management, followed by a more conservative follow-up such
as in this trial, may lead to fewer early and late complications, as (sur-
gical) interventions can often be prevented.
In conclusion, this double-blind placebo-controlled RCT shows
that pre-treatment with mifepristone prior to misoprostol signifi-
cantly increases the number of patients with a complete evacua-
tion of the uterus in the case of a medical treatment of EPL after
one week of expectant management. The implementation of this
proven safe regimen into (inter)national guidelines may lead to
an extensive improvement in the medical treatment of EPL
worldwide.
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